Dr Reddy's launches generic cancer drug in India
Follow The Hawk on Google News+ FollowAdvertisement

New Delhi: Dr Reddy's Laboratories on Monday said it has launched blood cancer drug Invista in the country.
The company's product is a formulation of Dasatinib that is bioequivalent to the innovator brand, Dr Reddy's Laboratories said in a statement.
Advertisement
Patent on Dasatinib is owned by Bristol-Myers-Squibb. The Indian patent has expired on April 12, 2020.
Also readFSSAI to initiate action against Bisleri over unsafe water sample
Invista, which is available in strengths of 50, 70 and 100 mg tablets, is indicated for the treatment of primarily Chronic Myeloid Leukemia (CML).
CML is a type of blood-cell cancer that begins in the bone marrow.
Advertisement
The median age of the patients in India is a decade earlier than the west, and every year about nine thousand new patients are diagnosed in the country.
"The development and launch of Invista is a significant step forward in improving access to medicines at an affordable price for CML patients in India," Dr Reddy's Laboratories CEO, Branded Markets (India and Emerging Markets), M V Ramana said.
—PTI
Get The Hawk first on Google
Add The Hawk as a preferred source and Google shows you more of our stories in Top Stories. Follow us on Google News too.
Advertisement








